Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).

Eric Raymond,P. Niccoli,Jean-Luc Raoul,Yung-Jue Bang,Ivan Borbath,Catherine Lombard-Bohas,Juan W. Valle,Peter Metrakos,D. Smith,Aaron I. Vinik,J Chen,Dieter Hoersch,Daniel Castellano,Hagen F. Kennecke,Joel Picus,G. Van Hazel,D. Lu,R. Chao,Shem Patyna,E. Van Cutsem

Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).

2011

4008 Background: In a double-blind phase 3 trial, SU improved PFS vs PBO (11.4 vs 5.5 months; HR 0.418, 95% CI 0.263, 0.662; p=0.0001) and was well tolerated in pts with advanced well-differentiate...

Keywords:

Progression-free survival
Pathology
Placebo
Neuroendocrine tumors
Sunitinib
Medicine
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations